- What Is Dementia?
- Take our Dementia Test
- Find a therapist to help with dementia
Key points
- Dementia is a common late-life disease with few treatments and devastating consequences.
- There are two distinct approaches to dementia: prevention and treating established disease.
- Current evidence is equivocal regarding treatment but stronger for prevention.
Sandra spends most Tuesday afternoons in a neurologist’s waiting room, scrolling on her phone while her mother finishes a cognitive assessment down the hall. Her mother was diagnosed with Alzheimer’s disease two years ago, and Sandra has spent those two years learning a hard truth: unlike most of the health crises she has faced in her family, this one comes with few good treatment options and a daunting road ahead
Sandra is 52. Alzheimer’s runs in her family, and she has started to wonder, privately in years past and then more overtly during the past two years, what her own future holds
Like millions of people struggling with a parent’s dementia diagnosis, Sandra has seen the headlines. GLP-1 medicines, the same drugs reshaping conversations about weight and diabetes, are now being discussed as a possible treatment for Alzheimer’s disease. She brought the question to her mother’s neurologist, Dr. Reyes, hoping for a reason to be optimistic
Dr. Reyes was careful. The evidence, she explained, is not yet strong enough to recommend a GLP-1 medicine as a treatment for Sandra’s mother. The research is real, but premature, and the results so far have been mixed
Then Dr. Reyes said something Sandra didn’t expect. Given Sandra’s family history, and that Sandra had already been considering a GLP-1 medicine for other conditions, the more promising conversation was not about treating her mother’s disease, but about possibly lowering her own risk
That distinction, between treating dementia and preventing it, turns out to be the most important thing to understand about this fast-moving area of research
Why Treatment Remains Uncertain
The excitement about GLP-1 medicines and Alzheimer’s disease is substantial, but so is the uncertainty. In late 2025, the two largest clinical trials ever conducted on a GLP-1 medicine and Alzheimer’s, testing semaglutide in people who already had mild cognitive impairment, failed to show that the drug slowed the disease’s progression.1 Around the same time, a separate and smaller trial of a related medicine, liraglutide, found the opposite: meaningfully less brain volume loss and slower cognitive decline in the treated group.2
Three well-designed studies, contradictory results. That is not a reason for despair, but it is the reason a physicians like Dr. Reyes aren’t recommending these medicines as an Alzheimer’s treatment. A major new trial, backed by a $100 million investment from the Alzheimer’s Association, is now underway specifically to help resolve the contradiction.3
The More Promising Story Is Prevention
While the treatment evidence remains unsettled, a separate body of research has been building: not about reversing dementia once it has started, but about whether GLP-1 medicines might lower the chances of it developing in the first place
This research comes with the major caveat that it observational. Rather than testing the medicine directly against a placebo in a randomized trial, researchers tracked groups of people already taking GLP-1 medicines for diabetes or weight loss, and compared their rates of developing dementia against similar people who were not
A persuasive pattern emerged (see above “Science Corner”). A 2024 analysis of more than 1 million patients with type 2 diabetes found a 70% lower rate of Alzheimer’s diagnosis among semaglutide users compared to those on insulin. A large 2025 study led by Cleveland Clinic researchers, drawing on two separate medical databases, found a significantly reduced Alzheimer’s risk associated with starting a GLP-1 medicine. A propensity-matched study of nearly 300,000 patients found a comparable 70% relative reduction in dementia risk. And a 2025 study published in the Annals of Internal Medicine used a research design called target trial emulation, built specifically to approximate what a randomized trial would show using real-world data, and still found a protective association.4-8
- What Is Dementia?
- Take our Dementia Test
- Find a therapist to help with dementia
The biological reasoning behind these findings is sound. Insulin resistance, chronic inflammation, and poor vascular health are all established contributors to how dementia develops in the brain, and all three are pathways that GLP-1 medicines are known to improve. A medicine that helps regulate blood sugar, reduce inflammation, and support healthy blood vessels is, at least in theory, doing exactly the kind of work that might help protect brain health over time
“Weighing” the Evidence
It’s worth being precise about what these studies can and cannot tell us. Observational research is useful, but it cannot fully rule out other explanations. People who start and stay on a GLP-1 medicine may simply be healthier, more engaged with their medical care, or different in other ways from people who don’t. Any of those differences could partly explain the pattern
Dementia Essential Reads
Magic Mushrooms and Terminal Lucidity
How the Nazis Stymied Alzheimer’s Disease Research
That is why the finding from one study is noteworthy: dementia risk did not differ between groups when researchers looked at everyone who started the medicine, but it dropped by 21 percent specifically among people who stayed on it continuously over several years.8 That kind of detail, a benefit tied to sustained use rather than simply filling a prescription, is the sort of pattern that makes a biological effect more plausible than a statistical coincidence
A Personalized Conversation to Consider
For someone who already has reasons to consider a GLP-1 medicine, family history of dementia, a personal health goal around weight or diabetes management, this research offers something worth discussing directly with a physician: not a promise, but an evidence-backed reason for additional hope
For someone without another medical reason to take these medicines, the current evidence does not yet support starting one for brain health alone. That may change as the ongoing trials report their results, but it would be getting ahead of the science to act on that basis today
Sandra left her mother’s appointment that Tuesday with the same uncertainty she came in with about her mother’s prognosis. But she left with something else too: a specific, doctor-endorsed reason to schedule a different appointment, with her own physician, to ask a question she had not thought to ask before
1. Cummings JL, Atri A, Sano M, Zetterberg H, Scheltens P, Knop FK, Johannsen P, Wichmann CA, Abschneider RM, Leon T, Feldman HH. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer’s disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet. 2026 May 30;407(10544):2167-2179. doi: 10.1016/S0140-6736(26)00459-9
2. Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z, Ridha B, Raza S, Livingston NR, Frangou E, Love S, Williams G, Lawrence R, Mcfarlane B, Archer H, Coulthard E, Underwood BR, Koranteng P, Karim S, Bannister C, Perneczky R, Prasanna A, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Holscher C, Mansouri A, Chester-Jones M, Holmes J, Tan T, Williams S, Ashraf A, Brooks DJ, Harrison J, Hinz R, Tadros G, Passmore AP, Ballard C. Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial. Nat Med. 2026 Jan;32(1):353-361. doi: 10.1038/s41591-025-04106-7.
3. Alzheimer’s Association. Alzheimer’s Association launches “PROTECT-Cog” study to test U.S. POINTER lifestyle and GLP-1 or similar drug to cut risk of cognitive decline. Press release. Published July 13, 2026. Accessed [accessed August 15, 2026]. https://aaic.alz.org/releases-2026/new-study-protect-cog-glp-1-dementia.asp
4. Wang W, Wang Q, Qi X, Gurney M, Perry G, Volkow ND, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with first-time diagnosis of Alzheimer’s disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimers Dement. 2024 Dec;20(12):8661-8672. doi: 10.1002/alz.14313
5. Zhang P, Mao C, Sun A, Yang Y, Hou Y, Fu Z, Babak T, Leverenz JB, Pieper AA, Luo Y, Cummings J, Cheng F. Real-world observations of GLP-1 receptor agonists and SGLT-2 inhibitors as potential treatments for Alzheimer’s disease. Alzheimers Dement. 2025 Sep;21(9):e70639. doi: 10.1002/alz.70639
6. Inoue K, Saliba D, Gotanda H, Moin T, Mangione CM, Klomhaus AM, Tsugawa Y. Glucagon-Like Peptide-1 Receptor Agonists and Incidence of Dementia Among Older Adults With Type 2 Diabetes : A Target Trial Emulation. Ann Intern Med. 2025 Sep;178(9):1258-1267. doi: 10.7326/ANNALS-24-02648
7. AbuAlrob MA, Itbaisha A, Abujwaid YK, Abulehia A, Hussein A, Mesraoua B. Exploring the neuroprotective role of GLP-1 agonists against Alzheimer’s disease: Real-world evidence from a propensity-matched cohort. J Alzheimers Dis Rep. 2025 Oct 16;9:25424823251388650. doi: 10.1177/25424823251388650
8. Wu CY, Alkabbani W, Shah BR, Kapral MK, Edwards JD, Maxwell CJ, Swardfager W. Comparative dementia risk with GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors: a population-based cohort study. Alzheimers Res Ther. 2025 Dec 20;17(1):269. doi: 10.1186/s13195-025-01929-x
